[HTML][HTML] When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
P Laneuville - Current treatment options in oncology, 2018 - Springer
Opinion statement Strict criteria for when to stop tyrosine kinase inhibitor (TKI) therapy in
clinical practice are not easily defined without an agreement on what probability of achieving …
clinical practice are not easily defined without an agreement on what probability of achieving …
Targeted therapy in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia
chromosome and oncogenic signaling by the resulting Bcr–Abl fusion protein …
chromosome and oncogenic signaling by the resulting Bcr–Abl fusion protein …
The role of new tyrosine kinase inhibitors in chronic myeloid leukemia
PA Pophali, MM Patnaik - The Cancer Journal, 2016 - journals.lww.com
Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …
[HTML][HTML] Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia-What to look for when treatment-free remission is not an option
JH Lipton, TH Brümmendorf, C Gambacorti-Passerini… - Blood Reviews, 2022 - Elsevier
The development of BCR:: ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …
[HTML][HTML] Advances in the treatment of chronic myeloid leukemia
Although imatinib is firmly established as an effective therapy for newly diagnosed patients
with chronic myeloid leukemia (CML), the field continues to advance on several fronts. In this …
with chronic myeloid leukemia (CML), the field continues to advance on several fronts. In this …
Treatment-free remission in patients with chronic myeloid leukaemia
In the past few years, international treatment guidelines for chronic myeloid leukaemia have
incorporated recommendations for attempting discontinuation of treatment with tyrosine …
incorporated recommendations for attempting discontinuation of treatment with tyrosine …
Getting to the stem of chronic myeloid leukaemia
M Savona, M Talpaz - Nature Reviews Cancer, 2008 - nature.com
Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is the
consummate success story for targeted therapy, yet relapse is a nearly inevitable …
consummate success story for targeted therapy, yet relapse is a nearly inevitable …
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
M Baccarani, E Abruzzese, V Accurso… - Blood …, 2019 - ashpublications.org
Several papers authored by international experts have proposed recommendations on the
management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these …
management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these …
[HTML][HTML] Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
JC Hernández-Boluda, A Pereira, I Pastor-Galán… - Blood cancer …, 2018 - nature.com
Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not
lose the major molecular response (MMR) after stopping treatment with tyrosine kinase …
lose the major molecular response (MMR) after stopping treatment with tyrosine kinase …
Revisiting six established practices in the treatment of chronic myeloid leukaemia
HM Kantarjian, MA Welch, E Jabbour - The Lancet Haematology, 2023 - thelancet.com
After two decades of use in chronic myeloid leukaemia, the risks and benefits of established
treatment practices for BCR:: ABL1 tyrosine kinase inhibitors (TKIs) in the chronic myeloid …
treatment practices for BCR:: ABL1 tyrosine kinase inhibitors (TKIs) in the chronic myeloid …